Pair Name	2,3,5,6-Tetramethylpyrazine, Cisplatin
Disease Info	[ICD-11: 2C10]	Pancreatic cancer		Investigative
Biological Phenomena	Induction-->Ferroptosis
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	CASP9	hsa842
	Up-regulation	Expression	CYCS	hsa54205
	Down-regulation	Expression	GPX4	hsa2879
	Down-regulation	Expression	NFE2L2	hsa4780
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Expression	SLC7A11	hsa23657
In Vitro Model	PANC-1/CDDP	Cisplatin-resistant pancreatic ductal adenocarcinoma	Homo sapiens (Human)	N.A.
In Vivo Model	The mice were inoculated subcutaneously with PANC-1/CDDP cells (1×10⁷/mouse) into the right flanks to establish PANC-1/CDDP xenograft models.
Result	A series of ligustrazine-derived chalcones-modified platinum(IV) complexes were synthesized and evaluated for their anti-proliferative potency and generated an optimal platinum(IV) complex 16a. The above-described results indicated that 16a obtained different anti-cancer mechanisms of CDDP, which could initiate mitochondria-dependent apoptosis and xCT-GPX4 axial-mediated ferroptosis in PANC-1/CDDP cells.